Dr. Michael C. Topf

Claim this profile

Vanderbilt University/Ingram Cancer Center

Studies Squamous Cell Carcinoma
Studies Skin Cancer
3 reported clinical trials
9 drugs studied

Affiliated Hospitals

Image of trial facility.
Vanderbilt University/Ingram Cancer Center
Image of trial facility.
Vanderbilt University Medical Center

Clinical Trials Michael C. Topf is currently running

Image of trial facility.

Sentinel Lymph Node Biopsy vs Neck Dissection

for Oral Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy surgery is a procedure that removes a smaller number of lymph nodes from your neck because it uses an imaging agent to see which lymph nodes are most likely to have cancer. Standard neck dissection, such as elective neck dissection, removes many of the lymph nodes in your neck. Using sentinel lymph node biopsy surgery may work better in treating patients with early-stage oral cavity cancer compared to standard elective neck dissection.
Recruiting1 award Phase 2 & 3
Image of trial facility.

89Zr Panitumumab PET/CT Imaging

for Head and Neck Cancer

The goal of this phase I clinical trial is to evaluate the usefulness of an imaging test (zirconium Zr89 panitumumab \[89Zr panitumumab\]) with positron emission tomography (PET)/computed tomography (CT) for diagnosing the spread of disease from where it first started (primary site) to other places in the body (metastasis) in patients with head and neck squamous cell carcinoma. Traditional PET/CT has a low positive predictive value for diagnosing metastatic disease in head and neck cancer. 89Zr panitumumab is an investigational imaging agent that contains radiolabeled anti-EGFR antibody which is overexpressed in head and neck cancer. The main question this study aims to answer is the sensitivity and specificity of 89Zr panitumumab for the detection of indeterminate metastatic lesions in head and neck cancer. Participants will receive 89Zr panitumumab infusion and undergo 89Zr panitumumab PET/CT 1 to 5 days after infusion. Participants will otherwise receive standard of care evaluation and treatment for their indeterminate lesions. Researchers will compare the 89Zr panitumumab to standard of care imaging modalities (magnetic resonance imaging (MRI), CT, and/or PET/CT).
Recruiting1 award Phase 1

More about Michael C. Topf

Clinical Trial Related5 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Michael C. Topf has experience with
  • Positron Emission Tomography
  • Zirconium Zr 89 Panitumumab
  • Computed Tomography (CT)
  • Imaging Agent
  • Neck Dissection
  • Planar Imaging

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Michael C. Topf specialize in?
Is Michael C. Topf currently recruiting for clinical trials?
Are there any treatments that Michael C. Topf has studied deeply?
What is the best way to schedule an appointment with Michael C. Topf?
What is the office address of Michael C. Topf?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security